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It remains uncertain whether the choice of resuscitation fluid for patients in intensive
care units (ICUs) affects survival. We conducted a multicenter, randomized, double-blind
trial to compare the effect of fluid resuscitation with albumin or saline on mortality in a




We randomly assigned patients who had been admitted to the ICU to receive either
4 percent albumin or normal saline for intravascular-fluid resuscitation during the next





Of the 6997 patients who underwent randomization, 3497 were assigned to receive al-
bumin and 3500 to receive saline; the two groups had similar baseline characteristics.
There were 726 deaths in the albumin group, as compared with 729 deaths in the saline
group (relative risk of death, 0.99; 95 percent confidence interval, 0.91 to 1.09; P=0.87).
The proportion of patients with new single-organ and multiple-organ failure was sim-
ilar in the two groups (P=0.85). There were no significant differences between the
groups in the mean (±SD) numbers of days spent in the ICU (6.5±6.6 in the albumin
group and 6.2±6.2 in the saline group, P=0.44), days spent in the hospital (15.3±9.6
and 15.6±9.6, respectively; P=0.30), days of mechanical ventilation (4.5±6.1 and





In patients in the ICU, use of either 4 percent albumin or normal saline for fluid resus-
citation results in similar outcomes at 28 days.
abstract
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he administration of intrave-
 
nous fluids to maintain or increase intra-
vascular volume is a common intervention
in the intensive care unit (ICU), but there is uncer-





 In particular, no ade-
quately powered randomized, controlled trials have
examined the effect of fluid choice on the survival
of patients in the ICU. In the absence of such trials,
a number of meta-analyses have examined how the
choice of crystalloid or colloid solution and of al-
bumin-containing or albumin-free fluid affects sur-





 A meta-analysis published by
the Cochrane Injuries Group Albumin Reviewers in-
cluded 24 studies involving a total of 1419 patients
and suggested that the administration of albumin-
containing fluids resulted in a 6 percent increase in
the absolute risk of death when compared with the





a subsequent meta-analysis of 55 trials involving a
total of 3504 patients examined the effect of resus-
citation with albumin-containing fluid on the risk
of death in a general population of patients and did




The conflicting results of such meta-analyses
have left many clinicians unsure about the effect of
albumin-containing fluids on survival in critically ill
patients. To address this uncertainty, we conducted
the Saline versus Albumin Fluid Evaluation (SAFE)
Study in 16 ICUs in Australia and New Zealand. We
tested the hypothesis that when 4 percent albumin
is compared with 0.9 percent sodium chloride (nor-
mal saline) for intravascular-fluid resuscitation in
patients in the ICU, there is no difference in the
28-day rate of death from any cause.
 
study design and treatment protocol
 
Patients 18 years of age or older who had been ad-
mitted to the closed, multidisciplinary ICUs of 16
academic tertiary hospitals in Australia and New
Zealand between November 2001 and June 2003
were assessed for eligibility for the study. Eligible
patients were those whom the treating clinician
judged to require fluid administration to maintain
or increase intravascular volume, with this decision
supported by the fulfillment of at least one objective
criterion. Patients admitted to the ICU after cardiac
surgery, after liver transplantation, or for the treat-
ment of burns were excluded. Details of the inclu-
sion and exclusion criteria are given in Table S1 of
the Supplementary Appendix (available with the full
text of this article at www.nejm.org). A detailed de-





The study protocol was approved by the ethics
committees of the University of Sydney and of each
participating institution. Written informed consent
was to be obtained from all competent patients; in
cases in which prior consent could not be obtained
from the patient because of critical illness or the use
of sedative or anesthetic drugs, consent could be de-
layed, and a provision for delayed consent was ap-
plied. In such cases, the patient or his or her surro-
gate decision maker was informed of the study as
soon as practicable, and consent was sought to con-
tinue the study procedures and to access the partic-
ipant’s medical records for study-related data. The
patients or their legal surrogates were informed of
their right to request that the study procedures be
discontinued and their right to refuse the study-
related use of their medical records.
Eligible patients were randomly assigned to re-
ceive either 4 percent albumin (Albumex, CSL) or
normal saline, with the random assignments strat-
ified according to institution and according to
whether there was a diagnosis of trauma on admis-
sion to the ICU. Randomization was carried out
centrally with the use of a minimization algorithm,
and the service was accessed on the Internet through
a secure Web site. Study fluids were supplied in
identical 500-ml bottles, and blinding was ensured
through the use of specially designed masking





 The effectiveness of the blind-
ing was confirmed in a formal study before the trial
was initiated. The treating clinicians determined the
amount and rate of fluid administration according
to each patient’s clinical status and response to treat-
ment. The allocated study treatment was to be used
for all fluid resuscitation in the ICU until death or
discharge or until 28 days after randomization. The
administration of intravenous fluids outside the ICU
was not controlled.
In addition to the study fluid, patients received
maintenance fluids, specific replacement fluids, en-
teral or parenteral nutrition, and blood products at
the discretion of the treating clinicians. The moni-
toring of central venous pressure, pulmonary-artery
catheterization, and all other aspects of patient care
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baseline assessment and follow-up 
data collection
 
Data collected at baseline included the Acute Phys-





well as information pertaining to diagnostic crite-




 (Table S2 of the Supplemen-





 Patients were identified as having trau-
matic brain injury at baseline if they had a history of




 while not sedated
of less than 14, and an abnormality consistent with
traumatic brain injury on a computed tomographic
scan of the head. The cardiovascular, respiratory,
renal, hematologic, and hepatic components of





 as described in Table S3 of the Supplemen-
tary Appendix, were recorded at the time of random-
ization, daily for the next seven days, and then every
third day until discharge from the ICU or until day
28. After randomization, the heart rate, central
venous pressure, mean arterial blood pressure, vol-
ume of study fluid administered, volume of non-
study fluid and blood products administered, net
fluid balance (calculated as the total fluid input
minus the total fluid output), use of mechanical
ventilation, and use of renal-replacement therapy
(intermittent or continuous hemodialysis, hemo-
filtration, or hemodiafiltration) were recorded dai-





The primary outcome measure was death from any
cause within 28 days after randomization. Second-
ary outcome measures were the survival time during
the first 28 days, the proportion of patients who had
one, two, three, four, or five new organ failures (de-
fined as a documented change in the cardiovascular,
respiratory, renal, hematologic, or hepatic compo-
nent of the SOFA score from 0, 1, or 2 at baseline to
3 or 4 during the ICU stay, where higher scores in-
dicate increasingly severe organ dysfunction), the
duration of mechanical ventilation, the duration of
renal-replacement therapy, and the duration of the
ICU and hospital stay.
Death from any cause within 28 days after ran-
domization was also examined in six predefined
subgroups according to the presence or absence of
trauma, the presence or absence of severe sepsis,
and the presence or absence of the acute respiratory
distress syndrome at baseline.
 
study and data management
 
Two preplanned interim analyses were performed
by an independent statistician after recruitment of
the first 2333 patients (33 percent of the planned
total) and the first 4666 patients (67 percent), and
the results were reviewed by the independent data-
monitoring committee.
The George Institute for International Health at
the University of Sydney performed the data man-
agement, the site management, and the data analy-
sis, independently of the funding agencies. The
manuscript was prepared by the writing committee
and was revised by the study investigators, who ap-




The trial was designed to enroll 7000 patients, there-
by providing a power of 90 percent to detect a 3 per-
cent difference in absolute mortality rates between
the two groups from an estimated baseline mortal-
ity rate of 15 percent. The data were exported from
the study database and analyzed with the use of
SPSS software (version 11.5). All analyses were per-
formed on an intention-to-treat basis. Where data
were missing, we report the number of available ob-
servations, and we make no assumptions about the
missing data.
Proportions were compared by means of the
chi-square test or Fisher’s exact test, and continu-
ous variables were compared by means of unpaired
t-tests. The results of comparisons of event rates in
the two groups are presented as relative risks with
95 percent confidence intervals. Survival times were
compared by means of the log-rank test and are pre-
sented as Kaplan–Meier curves without adjustment
for baseline covariates. Heterogeneity of treatment
effects among subgroups was assessed with the use






Seven thousand random assignments to a study
treatment were made (3499 to the albumin group
and 3501 to the saline group). Three patients mis-
takenly underwent randomization twice within 28
days; they were followed for 28 days beginning at
the time of the first randomization, and for purpos-
es of data analysis were considered part of the group
to which they were first assigned. Thus, the study
population comprised 6997 patients, 3497 of whom
results
Copyright © 2004 Massachusetts Medical Society. All rights reserved. 
Downloaded from www.nejm.org at EMORY UNIVERSITY on December 4, 2006 . 
 






















were assigned to receive albumin and 3500 of whom
were assigned to receive saline. The majority of the
patients (6628 [94.7 percent] — 3312 of those in
the albumin group [94.7 percent] and 3316 of those
in the saline group [94.7 percent]) were enrolled
with the use of the provision for delayed consent.
Delayed consent was obtained from the patient in
2713 cases (38.8 percent) and from a surrogate de-
cision maker (a relative, a legally recognized surro-
gate, or an institutional ethics committee) in the re-
maining cases. Prior consent was obtained from the
patient in 45 cases (0.6 percent) and from a surro-
gate decision maker in 335 cases (4.8 percent).
At baseline, the only statistically significant dif-
ference between the two groups was a higher mean
(±SD) central venous pressure in the albumin group
(9.0±4.7 mm Hg, vs. 8.6±4.6 mm Hg in the saline
group; P=0.03). The baseline characteristics of the
6997 patients are summarized in Table 1, and their
progress through the study is summarized in Fig-
ure S1 of the Supplementary Appendix.
Study fluid was administered to all but 197 pa-
tients (2.8 percent), including 90 in the albumin
group and 107 in the saline group. Resuscitation
fluids in addition to the allocated study fluid were
administered to 309 patients in the albumin group
(8.8 percent) and 375 in the saline group (10.7 per-
cent). The most common reason for the adminis-
tration of nonstudy resuscitation fluid was error (in
189 patients in the albumin group [5.4 percent] and
190 in the saline group [5.4 percent]). Clinicians’
preference for a specific nonstudy resuscitation flu-
id was the reason for its administration in 68 pa-
tients in the albumin group (1.9 percent) and 103
in the saline group (2.9 percent). At the completion
of the trial, information on vital status 28 days after
randomization was unavailable for 67 patients (1.0
percent), including 26 in the albumin group and 41
in the saline group. In 56 of these 67 cases, vital sta-
tus was missing because the patient or his or her le-
gal surrogate had withheld or withdrawn consent.
 
fluids administered and treatment effects
 
On each of the first three study days, the patients
who had been randomly assigned to receive albumin
received significantly less study fluid than did those
assigned to saline, resulting in a significantly great-
er net positive fluid balance in the saline group on
each of those days (Table 2). The ratios of the volume
of albumin to the volume of saline administered
during the first four days were as follows: 1:1.3 on
day 1, 1:1.6 on day 2, 1:1.3 on day 3, and 1:1.2 on
 
* Plus–minus values are means ±SD. Percentages were calculated according to 
the number of patients for whom data were available: for sex, 3497 in the albu-
min group and 3500 in the saline group; for severe sepsis, 3339 in the albumin 
group and 3338 in the saline group; and for all the other variables, 3428 in the 
albumin group and 3423 in the saline group. Because of rounding, not all per-
centages total 100. ICU denotes intensive care unit, and APACHE II Acute 
Physiology and Chronic Health Evaluation II.
† Higher scores on APACHE II indicate more severe illness.
‡P=0.03 for the comparison with the value in the albumin group (without cor-
rection for multiple-hypothesis testing).






of 3 or 4 for any individual organ system.
 
Table 1. Baseline Characteristics of the Patients.*
Characteristic Albumin Group Saline Group
 
Age — yr 58.6±19.1 58.5±18.7
Female sex — no. (%) 1424 (40.7) 1376 (39.3)







Source of admission to ICU — no. (%)
Emergency department 948 (27.7) 977 (28.5)
Hospital floor 614 (17.9) 573 (16.7)
Another ICU 63 (1.8) 66 (1.9)
Another hospital 323 (9.4) 341 (10.0)
Operating room (emergency surgery) 801 (23.4) 780 (22.8)
Operating room (elective surgery) 662 (19.3) 678 (19.8)
Same ICU (readmission) 17 (0.5) 8 (0.2)
Predefined subgroups — no. (%)
Trauma
Severe sepsis







APACHE II score† 18.7±7.9 19.0±8.0
Physiological variables
Heart rate — beats/min 91.4±23.5 92.3±23.5
Mean arterial pressure — mm Hg 77.8±16.4 78.2±16.3
Central venous pressure — mm Hg 9.0±4.7 8.6±4.6‡
Urine output — ml/hr 89.7±132.4 95.0±161.4
Serum albumin — g/liter 27.4±7.8 27.7±7.9
Organ failure— no. (%)§
No failure 1962 (57.2) 1885 (55.1)
1 organ 1075 (31.4) 1148 (33.5)
2 organs 335 (9.8) 329 (9.6)
3 organs 50 (1.5) 57 (1.7)
4 organs 5 (0.1) 4 (0.1)
5 organs 1 (<0.1) 0
Mechanical ventilation — no. (%) 2186 (63.8) 2217 (64.8)
Renal-replacement therapy — no. (%) 45 (1.3) 41 (1.2)
Albumin in previous 72 hr — no. (%) 127 (3.7) 135 (3.9)
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day 4. The overall ratio of the volume of albumin to
the volume of saline administered during the first
four days was approximately 1:1.4. Patients in the
two groups received similar volumes of other fluids
during the first four days, except on days 1 and 2,
when the patients in the albumin group received a
greater volume of packed red cells than did those in
the saline group; on average, during the first four
days, patients assigned to receive albumin received
71.0 ml more packed red cells than those assigned
to receive saline. On day 2, patients in the saline
group received a greater volume of nonstudy fluids
than did those in the albumin group (Table 2). After
day 4, there were no differences between the two
groups in the volume of study fluids administered.
There were no significant differences between the
groups in the mean arterial pressure measured at
the end of each of the first four days of the study. The
patients assigned to receive albumin had a lower
heart rate at the end of the first day than those as-
 
* Plus–minus values are means ±SD.
 
† P values are for the comparison between the two means for each variable at each time point.
 
Table 2. Fluids Administered and Physiological Effects of Treatment.*
Variable Albumin Group Saline Group P Value†
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signed to receive saline. Central venous pressure
was significantly higher in the albumin group than
in the saline group at all time points during the first
four days, and the serum albumin concentration was





Within 28 days after randomization, 726 of 3473 pa-
tients in the albumin group (20.9 percent) and 729
of 3460 patients in the saline group (21.1 percent)
had died. For the albumin group as compared with
the saline group, the absolute difference in mortal-
ity was –0.2 percent (95 percent confidence inter-
val, –2.1 to +1.8 percent). The relative risk of death
among patients assigned to receive albumin as
compared with those assigned to receive saline was
0.99 (95 percent confidence interval, 0.91 to 1.09;
P=0.87). At 28 days, 111 patients in the albumin
group (3.2 percent) and 87 patients in the saline
group (2.5 percent) remained in the ICU (relative
risk, 1.27; P=0.09); 793 (22.8 percent) and 848
(24.5 percent), respectively, remained in the hospi-
tal (relative risk, 0.93; 95 percent confidence inter-
val, 0.86 to 1.01; P=0.10) (Table 3). There was no
significant difference in survival times between the
two groups (Fig. 1).
The number of patients who had new single-
organ or multiple-organ failure, assessed according
to their SOFA scores, was similar in the two groups
(P=0.85 by Fisher’s exact test) (Table 3). During the
28-day study period the mean length of stay in the
 
* Plus–minus values are means ±SD. CI denotes confidence interval, and ICU intensive care unit.
† The data include the numbers of patients in the ICU or the length of stay in the ICU.





 of 0, 1, or 2 in any individual organ system at baseline, followed by an increase in the score to 3 or 4 in the 
same system.
§ The P value pertains to the comparison between the albumin and saline groups in the numbers of patients who had no new organ failure or 
 
new failure of one, two, three, four, or five organs.
 
Table 3. Primary and Secondary Outcomes.*




(95% CI) P Value
 
Status at 28 days — no./total no. (%)
Dead 726/3473 (20.9) 729/3460 (21.1) 0.99 (0.91 to 1.09) 0.87
Alive in ICU 111/3473 (3.2) 87/3460 (2.5) 1.27 (0.96 to 1.68) 0.09
Alive in hospital† 793/3473 (22.8) 848/3460 (24.5) 0.93 (0.86 to 1.01) 0.10
Length of stay in ICU — days 6.5±6.6 6.2±6.2 0.24 (–0.06 to 0.54) 0.44
Length of stay in hospital — days† 15.3±9.6 15.6±9.6 –0.24 (–0.70 to 0.21) 0.30
Duration of mechanical ventilation — 
days
4.5±6.1 4.3±5.7 0.19 (–0.08 to 0.47) 0.74
Duration of renal-replacement therapy 
— days
0.48±2.28 0.39±2.0 0.09 (–0.0 to 0.19) 0.41
New organ failure — no. (%)‡ 0.85§
No failure 1397 (52.7) 1424 (53.3)
1 organ 795 (30.0) 796 (29.8)
2 organs 369 (13.9) 361 (13.5)
3 organs 68 (2.6) 75 (2.8)
4 organs 18 (0.7) 17 (0.6)
5 organs 2 (0.1) 0 
Death within 28 days according to sub-
group — no./total no. (%)
Patients with trauma 81/596 (13.6) 59/590 (10.0) 1.36 (0.99 to 1.86) 0.06
Patients with severe sepsis 185/603 (30.7) 217/615 (35.3) 0.87 (0.74 to 1.02) 0.09
Patients with acute respiratory dis-
tress syndrome
24/61  (39.3) 28/66  (42.4) 0.93 (0.61 to 1.41) 0.72
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ICU was 6.5±6.6 days in the albumin group and
6.2±6.2 days in the saline group (P=0.44). The mean
length of stay in the hospital was 15.3±9.6 days and
15.6±9.6 days, respectively (P=0.30). The numbers
of days of mechanical ventilation and days of renal-





During the 28-day study period, the relative risk of
death among patients with trauma in the albumin
group as compared with such patients in the saline
group was 1.36; the corresponding relative risk of
death among patients without trauma was 0.96
(P=0.04 by the test for a common relative risk). This
difference in the relative risk of death was due to the
greater number of patients with trauma and an as-
sociated brain injury who died after random assign-
ment to albumin as opposed to saline: 59 of 241
such patients in the albumin group died (24.5 per-
cent), as compared with 38 of 251 such patients in
the saline group (15.1 percent) (relative risk, 1.62;
95 percent confidence interval, 1.12 to 2.34; P=
0.009). Among patients who had trauma without
brain injury, there was no difference between the
groups in terms of mortality: 22 such patients in
the albumin group (6.2 percent) and 21 in the sa-
line group (6.2 percent) died (relative risk, 1.00; 95
percent confidence interval, 0.56 to 1.79; P=1.00).
Among all the patients who had trauma (596 in the
albumin group and 590 in the saline group), there
were 81 (13.6 percent) deaths in the albumin group
and 59 (10.0 percent) in the saline group (relative
risk, 1.36; 95 percent confidence interval, 0.99 to
1.86; P=0.06) (Fig. 2 and Table 3).
In a subgroup analysis of patients with severe
sepsis, the relative risk of death during the 28-day
study period among those randomly assigned to re-
ceive albumin as opposed to saline was 0.87, as
compared with a corresponding relative risk of 1.05
among patients without severe sepsis (P=0.06 by
the test for a common relative risk). Of the 603 pa-
tients with severe sepsis who had been assigned to
receive albumin, 185 (30.7 percent) died, and of the
615 patients with severe sepsis who had been as-
signed to receive saline, 217 (35.3 percent) died (rel-
ative risk, 0.87; 95 percent confidence interval, 0.74
to 1.02; P=0.09) (Table 3). In a subgroup analysis of
patients with the acute respiratory distress syn-
drome, the relative risk of death among those as-
signed to receive albumin as opposed to saline was
0.93; the corresponding relative risk among patients
without this syndrome was 1.00 (P=0.74 by the test
for a common relative risk).
In this randomized trial, we found that the use of
4 percent albumin or normal saline for intravascu-
lar volume resuscitation in a heterogeneous popu-
lation of patients in the ICU resulted in equivalent
rates of death from any cause during the 28-day
study period. Requirements for mechanical venti-
lation and renal-replacement therapy, time spent in
the ICU and in the hospital during the 28-day study
period, and the time until death (among the patients
who died) were also equivalent. The proportion of
patients in the two groups in whom new single-
organ or multiple-organ failure developed were sim-
ilar. Our findings do not support the results of the
Cochrane Injuries Group Albumin Reviewers’ meta-
analysis, which suggested that the use of albumin
was associated with an increased mortality rate




Our study was conducted as a double-blind, ran-
domized trial. Albumin and saline are not consid-
ered equipotent intravascular volume expanders, but
their relative potencies have not previously been
examined in an adequately powered, blinded trial.
In our study, patients who were resuscitated with al-
bumin received less fluid than those who were re-
suscitated with saline. During the first four days,
discussion
 
Figure 1. Kaplan–Meier Estimates of the Probability of Survival.
 
P=0.96 for the comparison between patients assigned to receive albumin and 
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the ratio of albumin administered to saline admin-
istered was approximately 1:1.4. However, there
was no significant difference in mean arterial pres-
sure between the groups, and the differences in
central venous pressure and heart rate were small.
Thus, we believe that the patients in the two groups
were resuscitated to similar and acceptable end
points.
Our study was also a large, pragmatic study in a
population of patients subject to a large number of
concurrent interventions. We did not collect infor-
mation on all concurrent interventions performed in
the ICU. However, randomization was stratified ac-
cording to participating institution, so that each in-
stitution treated equal numbers of patients assigned
to saline or to albumin. As a result, we do not believe
that an imbalance in concurrent interventions could
have influenced the results.
Patients who were assigned to albumin received
a significantly greater volume of packed red cells
during the first two days of the study. The reasons
for this difference remain speculative but may in-
clude greater hemodilution with albumin than with
saline or increased blood loss with albumin due to
transient alterations in coagulation. In a study of
transfusion requirements in critically ill patients
conducted by Hébert and colleagues, a liberal trans-
fusion policy resulted in the administration of an
excess of 3.0 units of packed red cells. This was as-





 During the first four days
of our study, the excess volume of fluid transfused
in the albumin group averaged 71.0 ml per patient
(less than one quarter of a unit). Accordingly, we do
not believe this small excess in transfused volume
influenced the results.
Given that our study had insufficient power to
detect small but important differences in mortality
among the predefined subgroups, the results pro-
vide only limited evidence that the treatment effects
varied among these subgroups. The finding that pa-
tients with trauma might benefit more from resus-
citation with saline than patients without trauma
appears to be consistent with the results of a meta-
analysis by Choi et al., who suggested that colloid
resuscitation was associated with increased mortal-




 In our study, however,
the increased relative risk of death among patients
with trauma as compared with those without trau-
ma resulted from a small excess number of deaths
among patients who had trauma with brain injury,
whereas the meta-analysis by Choi et al. did not in-





In our study, the difference in mortality between
the albumin and saline groups among patients with
trauma involving brain injury should be interpreted
 
Figure 2. Relative Risk of Death from Any Cause among All the Patients and among the Patients in the Six Predefined 
Subgroups.
 
The size of each symbol indicates the relative number of events in the given group. The horizontal bars represent the 
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with caution. Patients with traumatic brain injury
constituted only 7 percent of the study population,
and the excess number of deaths in the albumin
group was only 21. In large studies, such subgroup





tion, the rate of death from any cause over a 28-day
period is not considered the most appropriate out-
come measurement with which to assess treatment
effects in patients with brain injury. Assessment of
mortality and functional neurologic status at least





trast with our findings in patients with trauma, the
comparison of the relative risk of death among pa-
tients with severe sepsis and those without severe
sepsis provides limited evidence of a treatment effect
that favors albumin in patients with severe sepsis.
It should be noted that such differences between
subgroups frequently occur by chance and that only
specifically designed and appropriately powered
studies can determine whether any such treatment
effects are real.
In conclusion, our study provides evidence that
albumin and saline should be considered clinically
equivalent treatments for intravascular volume re-
suscitation in a heterogeneous population of pa-
tients in the ICU. Whether either albumin or saline
confers benefit in more highly selected populations
of critically ill patients requires further study. Ac-
cording to the current state of knowledge, factors
that may influence the choice of resuscitation fluid
for a critically ill patient include the individual clini-
cian’s preference, the tolerability of the treatment,
its safety, and its cost.
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